United StatesHealth

DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down about 4% year over year, while gross margin improved to 61.7%.

Eli Lilly (NYSE:LLY) received U.K. approval for Foundayo on August 10 for adult weight management and insufficiently controlled type 2 diabetes.

Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of $753.2 million, up 38% from $544.8 million a year earlier.

Cardinal Infrastructure Group (NASDAQ:CDNL) reported second-quarter 2026 revenue of $226.9 million, up 114% year over year, with approximately 64% organic growth.

Cardinal Health (NYSE:CAH) reported fiscal fourth-quarter 2026 revenue of $63.7 billion, up 6%, while GAAP operating earnings rose 70% to $729 million.

BioHarvest Sciences (NASDAQ:BHST) reported second-quarter 2026 revenue of $8.8 million, up 3.8%, while gross margin slipped to 58%.

Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.

Organigram Global (NASDAQ:OGI) reported $145.1 million in third-quarter gross revenue alongside a net income of $105.5 million.

Philips (NYSE:PHG) raised Exor’s permitted ownership cap to 22% from 20% under an updated long-term relationship agreement.

JBS (NYSE:JBS) reported record second-quarter 2026 net sales of $23.9 billion, up 14% from $21 billion a year earlier.

Jazz Pharmaceuticals (NASDAQ:JAZZ) agreed to acquire privately held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy candidate ABS-1230 to its rare neurological disease portfolio.

Village Farms (NASDAQ:VFF) reported Q2 2026 consolidated net sales of $64 million, up 7% year over year, as cannabis revenue reached a record $53.5 million.